Lecanemab treatment for mild alzheimer’s disease with high risk of cerebral hemorrhage: a case report

This case suggests that, despite hemorrhage risks, lecanemab may have a manageable risk-benefit profile in selected real-world AD patients under intensive monitoring and multidisciplinary care, with its application beyond clinical trial criteria requiring more nuanced and individualized consideration.